Search results
Results from the WOW.Com Content Network
Neratinib (), sold under the brand name Nerlynx, is a tyrosine kinase inhibitor anti-cancer medication used for the treatment of breast cancer. [3] [4]The most common side effect is diarrhea, which affects nearly all patients. [4]
The agreement allowed the drug to be manufactured in the United States, which made it more accessible to patients and lowered the cost of brain cancer treatment by approximately 90%. The manufacturing agreement also resulted in lomustine once again being included in the Medicare federal drug discount program.
A deelgemeente (Dutch pronunciation: [ˈdeːlɣəˌmeːntə] ⓘ, literally sub-municipality), or section (French pronunciation: ⓘ), is a subdivision of a municipality in Belgium and, until March 2014, in the Netherlands as well.
The drug carrier releases the anti-cancer drug when triggered by the tumor's low pH levels and these pH levels control the rate of drug release. [16] Drugs administered usually require frequent dosing, but with a drug delivery carrier, it allows for a gradual and sustained release of the drug leading cancer patients to not have to be in the ...
The concept of the tumor microenvironment (TME) dates back to 1863 when Rudolf Virchow established a connection between inflammation and cancer. However, it was not until 1889 that Stephen Paget's seed and soil theory introduced the important role of TME in cancer metastasis, highlighting the intricate relationship between tumors and their surrounding microenvironment.
The Rotterdam Study or ERGO (Dutch: Erasmus Rotterdam Gezondheid Onderzoek) is a prospective, population-based cohort study. The aim of the Rotterdam Study is to investigate etiology , preclinical phase, prognosis and potential intervention targets of chronic diseases in mid- and late-life.
The drug (originally known as MT103) was developed by a German-American company Micromet, Inc. in cooperation with Lonza; In 2012, Micromet was purchased by Amgen, which furthered the drug's clinical trials. In July 2014, the FDA granted breakthrough therapy status to blinatumomab for the treatment of acute lymphoblastic leukemia (ALL). [12]
Pernis (Dutch pronunciation:) [1] is a neighborhood and submunicipality (since 3 March 2010) of Rotterdam, Netherlands. The district has a population of 4,845 (2018) on a total area size of 1.60 km 2 (0.62 sq mi). Pernis is thus a full submunicipality of Rotterdam, but the former independent municipality had its own district council already.